Explainable AI lessons from the developers of the EarliPoint Evaluation for autism

Healthcare can’t fully embrace artificial intelligence until it’s better understood — and this device developer says explainable AI is critical.

By Sreeni Narayanan, EarliTec Diagnostics

EarliTec’s EarliPoint device uses artificial intelligence for embedded eye-tracking technology that measures more than 120 focal preferences per second. [Photo courtesy of EarliTec Diagnostics]

Artificial intelligence (AI) now performs feats that would have seemed far-fetched just a short few years ago. Users simply enter prompts and then quickly receive proposed actions or substantive answers in response, with a potential impact in healthcare that seems virtually boundless.

However, the calculations that occur between point A and point B — or the input and the output — are a mystery to most people. How GPTs and other AI programs do what they do remains poorly understood. While for many industries the how may be of…

Read more
  • 0

FDA authorizes Cognoa autism spectrum disorder diagnostic aid

U.S. FDA today authorized Cognoa’s machine learning-based software to help diagnose autism spectrum disorder.

The de novo authorization from FDA covers the use of the Cognoa ASD Diagnosis Aid with children 18 months through 5 years of age with potential ASD symptoms. Palo Alto, Calif.–based Cognoa has touted the software as a way to do away with the time delays parents can experience as they try to schedule their children with specialists after a referral from a pediatrician.

“Autism spectrum disorder can delay a child’s physical, cognitive and social development, including motor skill development, learning, communication and interacting with others. The earlier ASD can be diagnosed, the more quickly intervention strategies and appropriate therapies can begin,” said Dr. Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health, in a news release.

The Cognoa ASD Diagnosis Aid uses a machine-learning algorithm to receive input fro…

Read more
  • 0